David Nierengarten
Stock Analyst at Wedbush
(4.44)
# 479
Out of 4,479 analysts
164
Total ratings
48.41%
Success rate
21.13%
Average return
Main Sectors:
Top Industries:
40 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Reiterates: Outperform | $519 | $435.49 | +19.18% | 13 | Jul 1, 2024 | |
| TSVT 2seventy bio | Reiterates: Neutral | $5 | $3.86 | +29.53% | 8 | Jun 27, 2024 | |
| IKNA Ikena Oncology | Downgrades: Neutral | $8 → $2 | $1.63 | +22.70% | 4 | May 29, 2024 | |
| COGT Cogent Biosciences | Reiterates: Neutral | $10 | $8.24 | +21.36% | 3 | May 24, 2024 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $5 | $2.98 | +67.79% | 5 | May 24, 2024 | |
| NUVL Nuvalent | Reiterates: Outperform | $99 | $73.00 | +35.62% | 3 | May 17, 2024 | |
| STRO Sutro Biopharma | Reiterates: Outperform | $8 | $2.96 | +170.27% | 6 | May 14, 2024 | |
| GBIO Generation Bio Co. | Reiterates: Outperform | $5 | $2.34 | +113.68% | 7 | May 14, 2024 | |
| ANAB AnaptysBio | Reiterates: Outperform | $34 | $23.94 | +42.02% | 10 | May 10, 2024 | |
| VOR Vor Biopharma | Reiterates: Outperform | $11 | $0.91 | +1,103.50% | 7 | May 10, 2024 | |
| XNCR Xencor | Maintains: Outperform | $34 → $36 | $18.26 | +97.15% | 6 | May 10, 2024 | |
| FATE Fate Therapeutics | Maintains: Neutral | $7 → $5 | $3.22 | +55.28% | 12 | May 10, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Outperform | $110 | $110.36 | -0.33% | 2 | Apr 26, 2024 | |
| TCRX TScan Therapeutics | Reiterates: Outperform | $10 | $5.73 | +74.52% | 3 | Apr 23, 2024 | |
| PRME Prime Medicine | Reiterates: Outperform | $12 | $5.28 | +127.27% | 3 | Apr 23, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $29 | $22.15 | +30.93% | 4 | Apr 23, 2024 | |
| BEAM Beam Therapeutics | Reiterates: Outperform | $57 | $22.57 | +152.55% | 3 | Apr 23, 2024 | |
| IMNM Immunome | Maintains: Outperform | $27 → $33 | $11.70 | +182.05% | 3 | Apr 1, 2024 | |
| BLUE bluebird bio | Maintains: Neutral | $3 → $1.68 | $0.92 | +82.00% | 1 | Mar 19, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $7.52 | +165.96% | 4 | Mar 12, 2024 | |
| MRSN Mersana Therapeutics | Upgrades: Outperform | $2 → $7 | $1.86 | +276.34% | 2 | Feb 29, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Outperform | $60 → $70 | $37.27 | +87.82% | 2 | Feb 26, 2024 | |
| GTHX G1 Therapeutics | Maintains: Outperform | $5 → $4 | $2.45 | +63.27% | 6 | Feb 13, 2024 | |
| INZY Inozyme Pharma | Reiterates: Outperform | $15 | $4.42 | +239.37% | 4 | Jan 30, 2024 | |
| KNSA Kiniksa Pharmaceuticals | Maintains: Outperform | $23 → $25 | $18.67 | +33.90% | 1 | Jan 2, 2024 | |
| MAXN Maxeon Solar Technologies | Maintains: Equal-Weight | $14 → $5 | $0.18 | +2,679.32% | 5 | Dec 8, 2023 | |
| ITOS iTeos Therapeutics | Reiterates: Outperform | $33 | $14.44 | +128.53% | 2 | Oct 18, 2023 | |
| CMRX Chimerix | Reiterates: Outperform | $6 | $0.86 | +595.65% | 2 | Aug 17, 2023 | |
| SRRK Scholar Rock Holding | Reiterates: Outperform | $24 | $7.63 | +214.55% | 5 | Aug 10, 2023 | |
| APGE Apogee Therapeutics | Initiates: Outperform | $40 | $38.21 | +4.68% | 1 | Aug 8, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Neutral | $7 → $4 | $0.80 | +400.00% | 5 | Jul 26, 2023 | |
| NVCR NovoCure | Upgrades: Neutral | $53 → $46 | $16.80 | +173.81% | 4 | Jun 7, 2023 | |
| YMAB Y-mAbs Therapeutics | Upgrades: Outperform | $5 → $13 | $11.37 | +14.34% | 2 | May 10, 2023 | |
| IRON Disc Medicine | Maintains: Outperform | $32 → $36 | $41.62 | -13.50% | 2 | Apr 26, 2023 | |
| FENC Fennec Pharmaceuticals | Maintains: Outperform | $11 → $19 | $6.03 | +215.09% | 3 | Sep 26, 2022 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | n/a | $40.96 | - | 6 | Oct 29, 2018 | |
| BOLD Boundless Bio | Maintains: Outperform | n/a | $4.30 | - | 1 | Oct 8, 2018 | |
| VYGR Voyager Therapeutics | Upgrades: Outperform | n/a | $7.59 | - | 2 | May 11, 2018 | |
| SYRS Syros Pharmaceuticals | Maintains: Outperform | n/a | $5.00 | - | 1 | Mar 13, 2018 | |
| PRTA Prothena Corporation | Downgrades: Neutral | n/a | $20.39 | - | 1 | Nov 20, 2017 |
argenx SE
Jul 1, 2024
Reiterates: Outperform
Price Target: $519
Current: $435.49
Upside: +19.18%
2seventy bio
Jun 27, 2024
Reiterates: Neutral
Price Target: $5
Current: $3.86
Upside: +29.53%
Ikena Oncology
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.63
Upside: +22.70%
Cogent Biosciences
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $8.24
Upside: +21.36%
Nuvation Bio
May 24, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.98
Upside: +67.79%
Nuvalent
May 17, 2024
Reiterates: Outperform
Price Target: $99
Current: $73.00
Upside: +35.62%
Sutro Biopharma
May 14, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.96
Upside: +170.27%
Generation Bio Co.
May 14, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.34
Upside: +113.68%
AnaptysBio
May 10, 2024
Reiterates: Outperform
Price Target: $34
Current: $23.94
Upside: +42.02%
Vor Biopharma
May 10, 2024
Reiterates: Outperform
Price Target: $11
Current: $0.91
Upside: +1,103.50%
Xencor
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $18.26
Upside: +97.15%
Fate Therapeutics
May 10, 2024
Maintains: Neutral
Price Target: $7 → $5
Current: $3.22
Upside: +55.28%
Blueprint Medicines
Apr 26, 2024
Reiterates: Outperform
Price Target: $110
Current: $110.36
Upside: -0.33%
TScan Therapeutics
Apr 23, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.73
Upside: +74.52%
Prime Medicine
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $5.28
Upside: +127.27%
Intellia Therapeutics
Apr 23, 2024
Reiterates: Neutral
Price Target: $29
Current: $22.15
Upside: +30.93%
Beam Therapeutics
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $22.57
Upside: +152.55%
Immunome
Apr 1, 2024
Maintains: Outperform
Price Target: $27 → $33
Current: $11.70
Upside: +182.05%
bluebird bio
Mar 19, 2024
Maintains: Neutral
Price Target: $3 → $1.68
Current: $0.92
Upside: +82.00%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $20
Current: $7.52
Upside: +165.96%
Mersana Therapeutics
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.86
Upside: +276.34%
SpringWorks Therapeutics
Feb 26, 2024
Maintains: Outperform
Price Target: $60 → $70
Current: $37.27
Upside: +87.82%
G1 Therapeutics
Feb 13, 2024
Maintains: Outperform
Price Target: $5 → $4
Current: $2.45
Upside: +63.27%
Inozyme Pharma
Jan 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $4.42
Upside: +239.37%
Kiniksa Pharmaceuticals
Jan 2, 2024
Maintains: Outperform
Price Target: $23 → $25
Current: $18.67
Upside: +33.90%
Maxeon Solar Technologies
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $14 → $5
Current: $0.18
Upside: +2,679.32%
iTeos Therapeutics
Oct 18, 2023
Reiterates: Outperform
Price Target: $33
Current: $14.44
Upside: +128.53%
Chimerix
Aug 17, 2023
Reiterates: Outperform
Price Target: $6
Current: $0.86
Upside: +595.65%
Scholar Rock Holding
Aug 10, 2023
Reiterates: Outperform
Price Target: $24
Current: $7.63
Upside: +214.55%
Apogee Therapeutics
Aug 8, 2023
Initiates: Outperform
Price Target: $40
Current: $38.21
Upside: +4.68%
Karyopharm Therapeutics
Jul 26, 2023
Maintains: Neutral
Price Target: $7 → $4
Current: $0.80
Upside: +400.00%
NovoCure
Jun 7, 2023
Upgrades: Neutral
Price Target: $53 → $46
Current: $16.80
Upside: +173.81%
Y-mAbs Therapeutics
May 10, 2023
Upgrades: Outperform
Price Target: $5 → $13
Current: $11.37
Upside: +14.34%
Disc Medicine
Apr 26, 2023
Maintains: Outperform
Price Target: $32 → $36
Current: $41.62
Upside: -13.50%
Fennec Pharmaceuticals
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $6.03
Upside: +215.09%
Ultragenyx Pharmaceutical
Oct 29, 2018
Maintains: Outperform
Price Target: n/a
Current: $40.96
Upside: -
Boundless Bio
Oct 8, 2018
Maintains: Outperform
Price Target: n/a
Current: $4.30
Upside: -
Voyager Therapeutics
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $7.59
Upside: -
Syros Pharmaceuticals
Mar 13, 2018
Maintains: Outperform
Price Target: n/a
Current: $5.00
Upside: -
Prothena Corporation
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $20.39
Upside: -